Paul Maier Sells 50,000 Shares of Eton Pharmaceuticals (NASDAQ:ETON) Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Director Paul Maier sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the sale, the director directly owned 59,745 shares in the company, valued at approximately $3,529,137.15. The trade was a 45.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Eton Pharmaceuticals Stock Performance

ETON opened at $59.78 on Friday. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of 157.32 and a beta of 0.86. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.52 and a quick ratio of 1.30. Eton Pharmaceuticals, Inc. has a 1-year low of $14.27 and a 1-year high of $66.37. The business has a 50 day moving average price of $45.17 and a two-hundred day moving average price of $31.90.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, August 13th. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.24. Eton Pharmaceuticals had a return on equity of 40.13% and a net margin of 12.02%.The company had revenue of $37.59 million for the quarter, compared to analysts’ expectations of $27.11 million. Research analysts predict that Eton Pharmaceuticals, Inc. will post 1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ETON. Craig Hallum boosted their price target on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. HC Wainwright upped their price target on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a report on Friday, August 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Canaccord Genuity Group raised their price objective on Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Finally, Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 13th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $67.50.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of large investors have recently made changes to their positions in ETON. Quarry LP acquired a new position in Eton Pharmaceuticals in the 3rd quarter worth approximately $37,000. Legal & General Group Plc acquired a new stake in Eton Pharmaceuticals during the 2nd quarter valued at $41,000. Toth Financial Advisory Corp purchased a new stake in shares of Eton Pharmaceuticals in the second quarter valued at $43,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Eton Pharmaceuticals in the fourth quarter valued at $44,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth $90,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.